User: Guest  Login
Title:

Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT.

Document type:
Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Article
Author(s):
Neuenhahn, M; Albrecht, J; Odendahl, M; Schlott, F; Dössinger, G; Schiemann, M; Lakshmipathi, S; Martin, K; Bunjes, D; Harsdorf, S; Weissinger, E M; Menzel, H; Verbeek, M; Uharek, L; Kröger, N; Wagner, E; Kobbe, G; Schroeder, T; Schmitt, M; Held, G; Herr, W; Germeroth, L; Bönig, H; Tonn, T; Einsele, H; Busch, D H; Grigoleit, G U
Abstract:
Cytomegalovirus (CMV) infection is a common, potentially life-threatening complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT). We assessed prospectively the safety and efficacy of stem cell-donor- or third-party-donor-derived CMV-specific T cells for the treatment of persistent CMV infections after allo-HSCT in a phase I/IIa trial. Allo-HSCT patients with drug-refractory CMV infection and lacking virus-specific T cells were treated with a single dose of ex vivo...     »
Journal title abbreviation:
Leukemia
Year:
2017
Journal volume:
31
Journal issue:
10
Pages contribution:
2161-2171
Language:
eng
Fulltext / DOI:
doi:10.1038/leu.2017.16
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/28090089
Print-ISSN:
0887-6924
TUM Institution:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie); Institut für Medizinische Mikrobiologie, Immunologie und Hygiene
 BibTeX